Case Study

Publicly Traded Pharmaceutical Company

The Fire

  • A publicly traded, biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases had its primary products fail initial clinical trials.
  • Public confidence and funding diminished, and the company determined to cease operations.

The Rescue

  • As Chief Liquidating Officer, addressed and solved remaining wind-down issues such as timely payment severance, financial reporting, collections, lease termination and related wind-down issues, including regulatory and archival issues connected to the failed clinical trials.

The Result

  • The wind-down was successfully transitioned in all financial reporting and related respects.
  • The company was successfully de-listed, and all required regulatory reports prepared and filed.
  • Issues of clinical trial regulatory compliance with other notable pharma companies was addressed and resolved.